We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
-3.85%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$1.91B
AUM Growth
-$201M
Cap. Flow
+$192M
Cap. Flow %
10.02%
Top 10 Hldgs %
65.78%
Holding
51
New
4
Increased
5
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
BDTX icon
Black Diamond Therapeutics
BDTX
+$105M
2
ELVN icon
Enliven Therapeutics
ELVN
+$64M
3
CSPR
Casper Sleep Inc.
CSPR
+$46.8M
4
TRIL
Trillium Therapeutics Inc.
TRIL
+$13.7M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$7.36M

Top Sells

Rank Stock Value
1
DERM
Dermira, Inc.
DERM
+$53.2M
2
SENS icon
Senseonics Holdings Inc
SENS
+$1.13M

Sector Composition

Rank Sector Weight
1 Healthcare 84.29%
2 Technology 12.73%
3 Consumer Discretionary 1.4%
4 Industrials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LQDA icon
26
Liquidia Corp
LQDA
$8.02B
$11.7M 0.61%
2,486,062
– –
XENE icon
27
Xenon Pharmaceuticals
XENE
$6.12B
$11.3M 0.59%
992,107
– –
OBSV
28
DELISTED
ObsEva SA Ordinary Shares
OBSV
$11.1M 0.58%
4,586,563
– –
AFMD
29
DELISTED
Affimed
AFMD
$9.68M 0.51%
612,649
– –
MRKR icon
30
Marker Therapeutics
MRKR
$18.7M
$9.5M 0.5%
500,000
– –
TPST icon
31
Tempest Therapeutics
TPST
$14.6M
$9.33M 0.49%
9,060
– –
AVEO
32
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$9.14M 0.48%
2,524,387
– –
SBBP
33
DELISTED
Strongbridge Biopharma plc.
SBBP
$7.83M 0.41%
4,141,308
– –
SYBX
34
DELISTED
Synlogic
SYBX
$7.28M 0.38%
281,961
– –
BE icon
35
Bloom Energy
BE
$64.6B
$6.97M 0.36%
1,333,333
– –
CTIC
36
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$6.57M 0.34%
7,140,450
+3,390,450
+90% +$3.89M
SURF
37
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$6.2M 0.32%
3,315,149
– –
RIGL icon
38
Rigel Pharmaceuticals
RIGL
$750M
$5.06M 0.26%
324,315
– –
VRNA
39
DELISTED
Verona Pharma
VRNA
$5.03M 0.26%
1,219,674
– –
LXRX icon
40
Lexicon Pharmaceuticals
LXRX
$1.1B
$4.65M 0.24%
2,382,286
– –
LUMO
41
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$4.48M 0.23%
+526,663
New +$7.36M
DZSI
42
DELISTED
DZS Inc. Common Stock
DZSI
$4.01M 0.21%
956,255
– –
PHXM
43
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$3.34M 0.17%
62,500
– –
XFOR icon
44
X4 Pharmaceuticals
XFOR
$460M
$3.33M 0.17%
11,111
– –
TRVN
45
DELISTED
Trevena, Inc.
TRVN
$2.16M 0.11%
6,099
– –
RGLS
46
DELISTED
Regulus Therapeutics
RGLS
$946K 0.05%
205,246
– –
AKTX
47
Akari Therapeutics
AKTX
$14.1M
$656K 0.03%
565
– –
TCON
48
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$589K 0.03%
17,336
– –
VIRX
49
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$539K 0.03%
37,094
– –
ELGX
50
DELISTED
Endologix Inc
ELGX
$172K 0.01%
249,022
+1
+0% +$1
1
2
3

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
DF
DNCA Finance Paris, France $1.75B AUM 38.18% 1-Year Est. Return
HHAM
HITE Hedge Asset Management Braintree, Massachusetts $1.77B AUM 38.67% 1-Year Est. Return
SFI
Siemens Fonds Invest Munich, Germany $1.75B AUM 26.24% 1-Year Est. Return
VCM
Valiant Capital Management San Francisco, California $1.74B AUM 64.05% 1-Year Est. Return

NEA Management Company's Q1 2020 Portfolio in Review

As of Q1 2020, NEA Management Company held 51 positions worth $1.91B, down 9.5% from $2.11B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

NEA Management Company deployed $192M of net new capital in Q1 2020, opening 4 new positions and adding to 5 existing holdings. Its largest new stake was Black Diamond Therapeutics: 3,449,845 shares worth $86.1M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 86% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Senseonics Holdings Inc, an estimated $1.13M trimmed.

  • NEA Management Company's largest Q1 2020 buy was Black Diamond Therapeutics: 3,449,845 shares worth $86.1M.
  • NEA Management Company added most to Trillium Therapeutics Inc. in Q1 2020, an estimated $13.7M increase.
  • NEA Management Company's biggest Q1 2020 reduction was Senseonics Holdings Inc, cutting an estimated $1.13M.
  • NEA Management Company fully exited Dermira, Inc. in Q1 2020, selling an estimated $53.2M.
  • NEA Management Company's ten largest holdings make up 66% of its $1.91B portfolio in Q1 2020.
  • NEA Management Company opened 4 new positions and closed 1 in Q1 2020.
  • NEA Management Company's portfolio value fell 9.5% quarter-over-quarter to $1.91B.

Based on NEA Management Company's 13F filing for Q1 2020, filed 6 May 2020.